Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer
2024

Macrophage Checkpoint Nanoimmunotherapy for Ovarian Cancer

publication Evidence: high

Author Information

Author(s): VandenHeuvel Sabrina N., Chau Eric, Mohapatra Arpita, Dabbiru Sameera, Roy Sanjana, O’Connell Cailin, Kamat Aparna, Godin Biana, Raghavan Shreya A.

Primary Institution: Texas A&M University

Hypothesis

Can lipid-based nanoparticles deliver siRNA to macrophages to disrupt CD47-SIRPα signaling in metastatic ovarian cancer?

Conclusion

The study demonstrates that using lipid nanoparticles to deliver siRNA can reduce SIRPα expression in macrophages, enhancing the effectiveness of chemotherapy against ovarian cancer.

Supporting Evidence

  • Macrophages in ovarian cancer spheroids increased chemoresistance and invasion.
  • siSIRPα LNPs significantly reduced SIRPα gene and protein expressions.
  • Disrupting CD47-SIRPα interactions sensitized ovarian cancer/macrophage heterospheroids to platinum chemotherapy.

Takeaway

This research shows that tiny particles can help deliver medicine to immune cells in cancer, making the cancer easier to treat.

Methodology

The study used lipid nanoparticles to deliver siRNA targeting SIRPα in macrophages within engineered tumor spheroids to assess effects on ovarian cancer progression.

Limitations

The study primarily focuses on in vitro models, which may not fully replicate in vivo conditions.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1021/acsabm.4c00076

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication